Show simple item record

dc.contributor.authorO'DRISCOLL, LORRAINEen
dc.date.accessioned2011-11-21T15:48:47Z
dc.date.available2011-11-21T15:48:47Z
dc.date.issued2010en
dc.date.submitted2010en
dc.identifier.citationWalsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Collins D, Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O'Driscoll L, Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis, British Journal of Cancer, 102, 2010, 1157 1162en
dc.identifier.otherYen
dc.descriptionPUBLISHEDen
dc.description.abstractBackground: Malignant melanoma, generally described as incurable, is notoriously refractory to chemotherapy. The mechanisms contributing to this have not yet been defined and the contributions of drug efflux pumps, implicated in chemo-resistance of many other cancer types, have not been extensively investigated in melanoma. Methods: In this study, expression of multi-drug resistant (MDR1/P-gp and MRP-1) proteins was examined, by immunohistochemistry, in archival specimens from 134 melanoma patients. This included 92 primary tumours and 42 metastases. Results: On assessing all specimens, MRP-1 and MDR1/P-gp expression was found to be common, with the majority (81%) of melanomas expressing at least one of these efflux pumps. Although there is significant association between expression of these pumps (P=0.007), MRP-1 was found to be the predominant (67% of cases) form detected. ?2 analysis showed significant associations between expression of MRP-1 and/or MDR1/P-gp and the aggressive nature of this disease specifically increased Breslow's depth, Clark's level and spread to lymph nodes. This association with aggressiveness and spread is further supported by the observation that a significantly higher percentage of metastases, than primary tumours, express MRP-1 (91% vs 57%; P<0.0001) and MDR1/P-gp (74% vs 50%; P=0.010). Conclusion: The predominant expression of these pumps and, in particular, MRP-1 suggests that they may be important contributors to the inherent aggressive and resistant nature of malignant melanoma.en
dc.description.sponsorshipThis work was supported by funding from Ireland's Higher Educational Authority Programme for Research in Third Level Institutions (PRTLI); Ireland's Health Research Board; Trinity College Dublin's Start-Up Funds for New Academics 2008/2009; and Science Foundation Ireland's funding of Molecular Therapeutics for Cancer, Ireland (08/SRC/B1410).en
dc.format.extent1157-1162en
dc.language.isoenen
dc.relation.ispartofseriesBritish Journal of Canceren
dc.relation.ispartofseries102en
dc.rightsYen
dc.subjectOncologyen
dc.subjectmalignant melanomaen
dc.subjectmultiple drug resistanceen
dc.titleMembrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasisen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/lodriscen
dc.identifier.rssinternalid64744en
dc.identifier.doi10.1038/sj.bjc.6605590.en
dc.subject.TCDThemeCanceren
dc.identifier.rssurihttp://www.ncbi.nlm.nih.gov/pubmed/20234362en
dc.identifier.orcid_id0000-0002-9860-8262en
dc.contributor.sponsorHealth Research Board (HRB)en
dc.contributor.sponsorHigher Education Authority (HEA)en
dc.contributor.sponsorScience Foundation Ireland (SFI)en
dc.identifier.urihttp://hdl.handle.net/2262/60883


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record